Association study between clinical response to rizatriptan and some candidate genes.
The aim of this study was to test genetic differences in the clinical response to rizatriptan in patients affected by migraine without aura. These genetic differences could be explained by various genes, the HTR1B, encoding the 5-HT(1) receptor subtype, MAOA gene that encodes the monoamino-oxidase, the main metabolic enzyme of this triptan, SLC6A4 (gene encoding the serotonin transporter) and DRD(2) (gene encoding the D(2) receptor), both involved in the pathogenesis of migraine. Fifty unrelated patients affected by migraine without aura (IHS) were included. Patients were divided into two groups (responders and non-responders) according to clinical response. Thirty-one out of fifty patients responded to rizatriptan. A significant difference among the two groups was observed in both allele (p=0.02) and genotype distribution (p=0.03) of DRD2/NcoI. The significant association with the DRD2/NcoI polymorphism in responders suggested that the DRD2/NcoI C allele may be considered a susceptibility factor heralding a good response to rizatriptan.
Asuni
Carlo
C
Section of Clinical Pharmacology, Department of Neurosciences B.B. Brodie, University of Galiari, P.O. San Giovanni di Dio, Via Ospedale 46, I-09124 Cagliari, Italy. carloasuni@tiscali.it
Cherchi
Allesandra
A
Congiu
Donatella
D
Piccardi
Maria P
MP
Del Zompo
Maria
M
Stochino
Maria E
ME
D000328:Adult; D000483:Alleles; D004351:Drug Resistance; D005260:Female; D005838:Genotype; D006801:Humans; D008297:Male; D008875:Middle Aged; D020326:Migraine without Aura / Q000188:drug therapy* / Q000235:genetics*; D008995:Monoamine Oxidase / Q000235:genetics; D011110:Polymorphism, Genetic; D011446:Prospective Studies; D044302:Receptor, Serotonin, 5-HT1B / Q000235:genetics; D017448:Receptors, Dopamine D2 / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction; D050486:Serotonin Plasma Membrane Transport Proteins / Q000235:genetics; D017366:Serotonin Receptor Agonists / Q000627:therapeutic use*; D016896:Treatment Outcome; D014230:Triazoles / Q000627:therapeutic use*; D014363:Tryptamines / Q000627:therapeutic use*
C470302:HTR1B protein, human; D044302:Receptor, Serotonin, 5-HT1B; D017448:Receptors, Dopamine D2; D050486:Serotonin Plasma Membrane Transport Proteins; D017366:Serotonin Receptor Agonists; D014230:Triazoles; D014363:Tryptamines; C093622:rizatriptan; D008995:Monoamine Oxidase